Our 1992 paper, 'The neural substrates of sensorimotor gating of the startle reflex: a review of recent findings and their implications', reviewed a series of (then) new and preliminary findings from cross-species studies of prepulse inhibition of the startle reflex, and commented on their implications. At the time that the report was composed, PubMed listed about 40 citations for studies using the search term 'prepulse inhibition' . In the ensuing 25 years, the field has added about 2700 such reports, reflecting the substantial growth in interest in prepulse inhibition and its utility across a number of different experimental applications. The 30th anniversary of the Journal of Psychopharmacology provides an opportunity to comment briefly on what was described in that 1992 report, how the field has progressed in the subsequent decades, and the paths forward for studies of prepulse inhibition and its use as an operational measure of sensorimotor gating. Among these future paths, we highlight the use of prepulse inhibition as: an endophenotype for genomic studies, and a biomarker for healthy brain circuitry, which may predict sensitivity to psychotherapeutics. Our 1992 report was highly speculative and based on paper-thin empirical data, yet viewed in a certain light, it appears to have contained a basic roadmap for a journey spanning the next 25 years of prepulse inhibition research… and 'what a long, strange trip it's been' .
Introduction
As part of this issue marking the occasion of the 30th anniversary of the Journal of Psychopharmacology, we were invited to comment on our 1992 publication, 'The neural substrates of sensorimotor gating of the startle reflex: a review of recent findings and their implications' (Swerdlow et al., 1992b ) -on its importance to the field, and on how the field has developed over the past quarter century. With this opportunity, we now revisit the content of that 1992 report, and the three major themes developed within it, including: (a) the concept that sensory, motor or cognitive 'gating' might be a 'domain of function' that is impaired across neuropsychiatric disorders that otherwise had been viewed as categorically distinct clinical entities -including schizophrenia, obsessive compulsive disorder (OCD), Tourette syndrome (TS), and Huntington's disease (HD), among others; (b) evidence that an operational measure of sensorimotor gating -prepulse inhibition (PPI) -could be demonstrated in cross-species studies to be regulated by specific neurochemical and anatomical substrates within the limbic cortex, striatum and pallidum, and the pontine tegmentum (limbic 'CSPP' circuitry); and (c) the observation that this limbic-motor circuitry appeared to be relevant to disorders characterized by impaired sensory, motor or cognitive 'gating'. Next, we review the PPI literature that has emerged subsequent to our 1992 publication, and identified areas of convergence and divergence between the perspectives and predictions raised in our report and the findings and directions of the PPI-relevant science that has taken place in these 25 years. Three introductory observations provide relevant context for this 'review and update' process.
First, our 1992 review described a substantial amount of unpublished data, from studies 'in progress'. In fact, at the time that this review was composed, the published neuropsychiatric literature related to PPI totaled about 40 papers, many of which addressed topics that were not directly related to the thematic focus of our review -i.e. brain mechanisms and neuropsychiatric disorders. Thus, much of the experimental 'evidence' described in our review -which spanned human and rodent studies, with complex pharmacological and neural circuit-based manipulations -was very preliminary. How we were able to publish a 'review' with so much speculation, based on very preliminary data, remains somewhat mysterious to us. But it happened nonetheless, and we are happy to attribute this fact to the wisdom and foresight of the editorial leadership of this journal.
Second, since the submission of our 1992 review, the PPI literature has added approximately 2700 new PubMed articles (Figure 1) , at a rate that accelerated in the five years after the publication of this review, and that has remained robust and increasing at a linear pace since that time. Many of these subsequent publications address topics that are thematically related to those described in our 1992 paper, while others address areas that were unanticipated at the time of our report -particularly those related to the genetic regulation of PPI, reflecting the genetic and molecular 'revolution' in the neurosciences that has transpired over the past 25 years. We can only comment selectively on this extensive literature; more comprehensive reviews can be found elsewhere (e.g. Powell, 2010; Powell and Geyer, 2002; Powell et al., 2009 Powell et al., , 2012 Swerdlow et al., 2008) .
Third, it is impossible to try to credit any single report as the 'first' or 'original' source of specific ideas or conceptualizations in our field, but our 1992 review -like many reports that we have written in the ensuing decades -took great care in its introductory sections to acknowledge the formative studies of the startle reflex and the 'primary startle circuit', conducted and reported by Michael Davis and colleagues in the 1970s and early 1980s (see Davis, 1984) . While our 1992 focus on PPI, its regulation by the basal forebrain, and the broader relevance of deficient gating mechanisms to human brain disorders, represented a departure from the literature of that day, it was only possible to make such conceptual advances because of the solid foundational work from Davis and colleagues, related to the neurophysiology of mammalian startle. With this foundation as a 'leaping point', the wild speculation within our 1992 review can mostly be assigned to three broad themes.
Theme 1: PPI is impaired across categorically distinct neuropsychiatric disorders
While it is now clear that PPI deficits are not clinically specific, the real catalyst behind the intense investigation of PPI came from the initial reports of PPI deficits in schizophrenia patients, from studies conducted in the laboratory of Enoch Callaway . Our review presented data both from this original 1978 report, and also from the second report of PPI deficits in schizophrenia patients, which was published contemporaneously with our review . Findings of deficient PPI in schizophrenia spectrum patients have since been replicated in almost 40 reports in the literature (cf. Swerdlow et al., 2014) , despite the emergence and nearly ubiquitous use of PPI-enhancing antipsychotics during the ensuing decades -a clinical reality that makes PPI deficits more difficult to detect and quantify (e.g. Kumari et al., 1999; Weike et al., 2000) .
Our 1992 review, however, made the new suggestion that a loss of automatic inhibitory mechanisms might underlie symptoms not only in schizophrenia, but also in other brain disorders, such as those characterized by intrusive thoughts and images (e.g. OCD), sensations (e.g. TS) and movements (e.g. HD). We speculated that such deficient inhibition might be accompanied by reduced levels of PPI. The basis for such speculation, also developed in our review, was the evolving evidence for the role of limbic cortico-striato-pallido-thalamic (CSPT) circuitry in both the regulation of PPI, and in the pathophysiology of these other brain disorders (e.g. Swerdlow and Koob, 1987) . At the time of the 1992 review, our only 'hard' evidence for PPI deficits in patient groups came from patients with schizophrenia, although our 1992 paper also included unpublished and nascent PPI data from just nine HD patients.
Over the ensuing decades, a number of studies have tested our speculation of PPI deficits across multiple brain disorders and confirmed that -in addition to the reduction of PPI in schizophrenia populations, PPI is also impaired in cohorts of patients with OCD (Ahmari et al., 2012; Hoenig et al., 2005; Kohl et al., 2015; Swerdlow et al., 1993b) , TS (Buse et al., 2016; Castellan Baldan et al., 2014; Castellanos et al., 1996; Swerdlow et al., 2001b; Zebardast et al., 2013) , and HD (Munoz et al., 2003; Swerdlow et al., 1995; Valls-Solé et al., 2004) . In addition, PPI deficits have been identified in other patient populations, including individuals with nocturnal enuresis (Ornitz et al., 1992) , Asperger's syndrome (Howlin and Murphy, 2002; McAlonan et al., 2002) , 22q11 syndrome (Sobin et al., 2005) , Kleinfelter syndrome (van Rijn et al., 2011) , fragile-X syndrome (Frankland et al., 2004; Renoux et al., 2014; Yuhas et al., 2011) , and blepharospasm (Gomez- Wong et al., 1998) . Some of these studies have used PPI as a quantitative phenotype to understand better the genetics (e.g. Castellan Baldan et al., 2014; Greenwood et al., 2012 ), neuropathology (e.g. McAlonan et al., 2002 , and treatment (e.g. Kohl et al., 2015) of these disorders, often engaging a range of cross-species models of PPI in the process (e.g. Angelov et al., 2014; Baldan Ramsey et al., 2011; Brooks et al., 2012; Carter et al., 1999; Shilling et al., 2008) . The role of psychotropic medications and other demographic and clinical variables in some of these clinical phenotypes has also been tested in many reports (e.g. Ahmari et al., 2012; Swerdlow et al., 2006) .
As these advances in the PPI literature were emerging, the fact that PPI deficits were being identified in so many different brain disorders was viewed by some as 'problematic' evidence that reduced PPI was 'non-specific' for a particular clinical diagnosis. In fact, what has become clear via a preponderance of evidence is that PPI is regulated by descending forebrain circuitry, and -as discussed below -disturbances throughout this circuitry accompany a wide range of diagnostically diverse psychiatric disorders -something that was proposed well before our 1992 review (e.g. Swerdlow and Koob, 1987) . However, it is also critical to note that PPI (and presumably its underlying neural regulation) appears to remain relatively intact, or at least functional, in a number of other serious brain disorders, including attention deficit disorder (ADHD; Castellanos et al., 1996; Conzelmann et al., 2010; Feifel et al., 2009; Hanlon et al., 2012; Ornitz et al., 1992 Ornitz et al., , 1999 , high functioning autism (Kohl et al. 2014) , bipolar disorder (in euthymic states; Barrett et al., 2005; Carroll et al., 2007 ; but see Sanchez-Morla et al., 2016) , and major depressive disorder (Ludewig and Ludewig, 2003; Perry et al., 2004; Quednow et al., 2006) , while evidence from chronic substance use disorders is mixed and likely to be substance specific (e.g. Quednow et al., 2004; Schellekens et al., 2012) . We assume that other 'negative' findings of intact PPI in other patient groups have gone unreported.
Theme 2: Limbic CSPP circuitry regulates PPI
Prior to our 1992 review, a handful of studies had investigated the neural regulation of PPI (e.g. Groves et al., 1974) . A focus on the role of the ventral striatum/nucleus accumbens (NAC) emerged from evidence that startle inhibition by pulsating tactile tail pressure was eliminated after NAC ablation (Sorenson and Swerdlow 1982) . This focus on the NAC has been substantiated by numerous subsequent reports, and 30+ years later, the NAC remains a crucial structure in current models for the regulation and dysregulation of PPI (e.g. Bikovsky et al., 2016; Ma and Leung, 2016; Vadnie et al., 2016) . But a key concept introduced by our 1992 review was that of a regulation of PPI by inter-connected CSPT circuitry -of which the NAC was one component -and which accessed pontine startle circuitry via descending efferent projections from the ventral pallidum into the pedunculopontine nucleus (PPTg; hence cortico-striato-pallido-pontine, or 'CSPP' circuitry); it was this latter structure, we proposed, that served to transmit the regulatory 'tone' established within the forebrain circuit to the primary startle circuit, and thereby alter the inhibitory impact of the lead stimulus (prepulse) on the startle reflex. As with our speculation about PPI in human brain disorders, this speculation about neural circuitry was based on thin 'circuitlevel' evidence, consisting of a few published reports (Caine et al., 1991 Swerdlow et al., 1986 Swerdlow et al., , 1990a Swerdlow et al., , 1990b Swerdlow et al., , 1990c , and some unpublished data described in this 1992 review (e.g. 10 rats with PPTg lesions).
Over the subsequent decades, compelling evidence for CSPP and related circuit involvement in the regulation of PPI has come through many different levels of experimental manipulations, as reviewed elsewhere (e.g. Swerdlow et al., 2001a Swerdlow et al., , 2008 . Elegant scientific strategies have added cellular -(e.g. Ma and Leung, 2016; Takahashi et al., 2007) and molecular (e.g. Culm et al., 2004) levels of resolution to PPI circuit models. Space constraints preclude a full review of this extensive literature. Nevertheless, we will comment on three points.
First, the apparent overlap in the neural substrates regulating PPI with those implicated in the pathophysiology of human brain disorders is part of the support for the etiological validity of animal models for impaired PPI in these disorders, and has been used in an iterative cross-species strategy. In this strategy, PPI changes after neural circuit manipulations in laboratory animals have been used to develop and then test hypotheses about specific circuit disturbances in patients (e.g. Kumari et al., 2003) , and in some cases, circuit-based therapeutics are being modeled based on PPI deficits in rats (e.g. Angelov et al., 2014; Ma and Leung, 2014) . Often, when substrates have been demonstrated to regulate PPI in rodents, the fact that PPI is deficient in patients has been used as the basis for justifying a fine grain analysis of those substrates in rats, in terms of their anatomical, neurochemical, and molecular properties. In turn, information about the detailed characteristics of this circuitry derived from studies in rodents has been used to support, develop, or test hypotheses regarding the nature of neural circuit disturbances in human brain disorders (e.g. Hines et al., 2013; Miller et al., 2010) . This iterative process of cross-species translation follows a bench-to-bedside model that is espoused across our field, and which is made feasible in the case of PPI based on the closely analogous, if not homologous, aspects of the experimental paradigm across mammalian species.
Second, much of the focus of the neural circuit-based translational models of PPI has been on the regulation of PPI by brain dopamine systems, and the potential utility of this neural mechanism in predictive models for antipsychotic medications. The focus on the PPI-regulatory role of NAC dopaminergic systems (Swerdlow et al., 1986) and dopamine activity more broadly was initially motivated by the prevailing hypothesis of a causative role of dopamine hyperfunction in the etiology of schizophrenia. The finding that PPI was disrupted in rodents by dopamine agonists Swerdlow et al., 1986) was applied in a manner prescribed for animal models of that era, by assessing the ability of this pharmacological effect to predict the antipsychotic potential and potency of established and novel compounds (cf. Geyer, 1993a, 1993b; Swerdlow et al., 1991 Swerdlow et al., , 1994 . This approach differed from pre-existing predictive models, such as apomorphine-induced canine emesis (Janssen and Niemegeers, 1959) , primarily because the behavior being measured (PPI) as a predictive index was very similar, if not homologous, across species. Our 1992 review included a partial listing of antipsychotics and (largely unpublished) data supporting the ability of these antipsychotics to prevent the apomorphine-induced disruption of PPI in Sprague-Dawley rats, and showed their relative clinical potency in schizophrenia (see Table 1 in Swerdlow et al., 1992b) . These data were expanded and reported soon thereafter (Swerdlow et al., 1994) , showing an expanded list of known antipsychotic compounds that prevented the PPI-disruptive effects of apomorphine, with their potency in this assay correlating highly (R=0.99) with their clinical antipsychotic potency. This compelling relationship was a catalyst for the use of PPI within a model with predictive validity, and led to the identifi-cation or validation of compounds with novel antipsychotic properties (e.g. ICI 204,636 (quetiapine; Swerdlow et al., 1994) ).
This predictive model was expanded significantly by the observation that putative antipsychotics with novel chemical properties were distinguished by their ability to block the PPI-disruptive effects of NMDA antagonists (Bakshi et al., 1994; Johansson et al., 1994) coupled with the inability of most typical antipsychotics to prevent these effects of NMDA antagonists (Keith et al., 1991) . Indeed, the prevailing wisdom of the 1990s was that the ability to prevent the PPI-disruptive effects of NMDA antagonists such as phencyclidine and ketamine might predict properties unique to 'atypical' or second generation antipsychotics (SGAPs), and thereby identify agents that would be both more clinically effective and better tolerated than first generation antipsychotics. Over time, this approach ran into some experimental and clinical headwind. First, the ability to prevent NMDA antagonist-induced PPI deficits was not always specific to SGAPs (e.g. chlorpromazine blocks the PPI-disruptive effects of ketamine (Swerdlow et al., 1998) ) or particularly sensitive to SGAPs (e.g. several studies reported either marginal or no ability of clozapine to prevent the PPI-disruptive effects of phencyclidine in rats). Second, and more importantly, clinical experience revealed that the benefits of SGAPs over older, first generation antipsychotics were not robust, and in fact SGAPs carried a new and non-trivial list of adverse properties. Thus, while the predictive validity of these PPI models for antipsychotics was further extended in many informative ways as reviewed previously (e.g. Geyer et al., 2001; Swerdlow et al., 2008) , they ultimately must be seen in the more humbling context of the clinical reality that antipsychotics of any generation are not well tolerated, and have palpable but limited ability to enhance real world function and improve the quality of life of schizophrenia patients (e.g. Lieberman et al., 2005) .
A third comment on the 'PPI-regulatory neural circuit' introduced in this 1992 review, is that the proposed 'circuit' was based on studies conducted largely in rats. Among the most dramatic and influential shifts in preclinical studies of PPI to emerge in the ensuing decades has been the preponderance of studies conducted in other species -particularly mice -driven largely by the utility of mice for studies with molecular and genetic levels of analysis (e.g. Francis et al., 2003) . While the neurochemical and neuroanatomical substrates of PPI in rats translated broadly to studies in mice (e.g. the involvement of forebrain monoamine and NMDA systems, the hippocampus and ventral forebrain, etc.), it became evident early in studies of 'mouse PPI' that finer grain analyses revealed distinctions and even opposite roles for specific receptor subtypes and circuit elements in the regulation of PPI across these two rodent species (cf. Geyer et al., 2002) . In particular, convergent pharmacological and genetic assessments of the influences of dopamine receptor subtypes on PPI demonstrated substantial differences between rats and mice (Ralph-Williams et al., 2002; . Hence, caution is warranted before extrapolating to mice the well-validated rat PPI model using dopamine agonists to identify antipsychotic treatments.
The biology (and particularly the genetics) of mouse PPI has evolved into a complex and powerful science beyond the scope of this review, but two points deserve comment: (a) the fact that the neurochemical regulation of PPI differed even among rats from different genetic backgrounds was recognized as early as 1990 , has in some cases been tracked down to its underlying molecular and neural circuit substrates (e.g. Palmer et al., 2000; Qu et al., 2009; Shilling et al., 2008; Swerdlow et al., 2011) , and is recapitulated among mice with different genetic backgrounds (e.g. Caine, 2005, 2007) ; (b) the fact that some aspects of the neural regulation of PPI can differ between two strains of mice or rats presents daunting challenges when trying to extrapolate findings from rodents to humans .
At the same time, the fact that some PPI-regulatory neural mechanisms are conserved across species, from zebrafish (in whom PPI is disrupted by apomorphine and restored by antipsychotics; Burgess and Granato, 2007) , mice, rats, guinea pigs (Sipes and Geyer, 1996; Vaillancort and Boksa, 2000) , pigs (Lind et al., 2004) , lower primates (Linn et al., 2003) and higher primates (Talledo et al., 2009 ), continues to make PPI an appealing measure for cross-species analyses of neural circuit connectivity.
Theme 3: PPI-regulatory circuitry is relevant to disorders characterized by impaired sensory, motor or cognitive 'gating'
The third area of speculation within our 1992 'review' was that the neural substrates of PPI are relevant to disorders of impaired sensory, cognitive or motor 'gating'. Implicit in this concept is the notion that PPI might be useful as a 'read-out' of CSPP function and dysfunction, and thus could be used to guide the development of interventions for these brain disorders ( Figure 2 ). Over the past 25 years, this concept has, on occasion, been misinterpreted to suggest that deficient PPI 'causes' clinical symptoms, to which our standard response is that no patient, to our knowledge, has ever complained that their startle is not inhibited enough by prepulses.
Rather, we have viewed PPI as a convenient pontine 'portal' from which to observe descending forebrain activity that, in addition to regulating PPI, may be relevant to the clinical syndromes associated with a group of disorders. We specifically proposed this notion in our 1992 review, in a section entitled, 'Are these substrates relevant to disorders of deficient cognitive and sensorimotor gating?' The information applied towards this question in the ensuing decades has taken a bidirectional route, from 'bedside' -for example, neuroimaging studies of OCD (Schwartz et al., 1996) and neuropathological studies of schizophrenia (Lewis et al., 2005) and TS (Kataoka et al., 2010) -to 'bench', and from 'bench' -for example, neurodevelopmental models of schizophrenia (Lipska et al., 1995) , kindling models of temporal lobe epilepsy (TLE; Wolf et al., 2016) and gene 'knock-out' models of TS (Castellan Baldan et al., 2014) -to bedside.
The clinical evidence for CSPP and CSPT dysfunction in psychiatric disorders is now extensive, and since our original hypothesis paper in 1987 (Swerdlow and Koob, 1987) , has been reviewed numerous times (e.g. most recently by Gunaydin and Kreitzer, 2016) . We will touch briefly on the findings that have since flowed from the 'benchside', supporting the hypothesis that this 'gating circuitry' is relevant to human brain disorders.
Because the first (and for some years, the only) evidence for human PPI deficits came from studies in schizophrenia patients, early neural circuit manipulation in animal studies of PPI focused on substrates implicated in this disorder, for example, forebrain dopamine mechanisms (Sorenson and Swerdlow, 1982; Swerdlow et al., 1986) . Starting in the early 1990s, this focus expanded to include the prefrontal cortex (PFC) and mesial temporal lobe regions, in addition to ventral pallidum and thalamic structures, that figure prominently in models of schizophrenia neuropathology (cf. Swerdlow et al., 1992a Swerdlow et al., , 1992b 2001a , 2001b 2008; Rohleder et al., 2014) . The apparent overlap in the neural substrates regulating PPI, with those implicated in the pathophysiology of schizophrenia, supported the etiological validity of animal models for impaired PPI in schizophrenia; this etiological validity is strengthened by the fact that experimental manipulations in rodents that are thought to model some of the suspected pathogenic insults responsible for schizophrenia also produce adult rodents with deficient PPI.
For example, in schizophrenia patients, the integrity of the hippocampal-PFC connection is disrupted, and the level of this deficiency predicts both neurocognitive and functional impairment (e.g. Hanlon et al., 2012) . Lesions of the ventral hippocampus (VH) in neonatal rats recreate a number of deficits associated with schizophrenia (Lipska et al., 1993; Marquis et al., 2006; cf. O'Donnell, 2012) , including deficient PPI (Daenen et al., 2003; Le Pen and Moreau, 2002; Le Pen et al., 2003; Lipska et al., 1995; Swerdlow et al., 2012) . The use of deficient PPI as a validating 'phenotype' in this model has been expanded to several different early developmental insults of the mesial temporal lobe that produce PPI deficits in adulthood, including immune/inflammatory activation of the VH (e.g. Ribeiro et al., 2013; Zhu et al., 2014a) , neonatal pilocarpine-induced seizures (Labbate et al., 2014) , cell-type-specific inhibition of the VH (Nguyen et al., 2014) and neonatal lesions of the basolateral amygdala (Vázquez-Roque et al., 2012) .
Other in utero or neonatal manipulations also produce PPI deficits in adult rats, including social isolation rearing (Geyer et al., 1993) , methylazoxymethanol exposure (Le Pen et al., 2006) , and neonatal administration of NMDA antagonists (Uehara et al., 2010) . Presumably, the failure to develop normal levels of PPI in these developmental models could reflect many different underlying mechanisms. In some cases, the expression of PPI deficits induced by these early developmental manipulations can be blocked by acute treatments during adulthood, using antipsychotics (e.g. clozapine; Ribeiro et al., 2013) , putative neuroprotective agents (e.g. minocycline; Zhu et al. 2014b) and glycinergic agents (Le Pen et al., 2003) .
While the past 25 years has produced substantial 'bidirectional' support that PPI-regulatory circuitry is relevant to disorders such as schizophrenia, OCD, TS, TLE and others, it has also yielded clear evidence that the absolute level of PPI does not suggest either the presence or absence of pathology in this circuitry. Thus, among healthy humans, there is a wide range of basal levels of PPI; conversely, PPI can be 'normalized' in severely ill schizophrenia patients by SGAPs, which clearly do not substantially 'normalize' their clinical state or CSPP dysfunction. Perhaps the clearest evidence that reduced PPI suggests neither circuit nor clinical dysfunction comes from findings of sex differences (Swerdlow et al., 1993a) and menstrual cyclicity (Jovanovic et al., 2004; Kask et al., 2008; Swerdlow et al., 1997) of PPI in healthy humans.
Future directions?
Predicting the future directions for PPI research in 1992 -when PPI science was largely a 'tabula rasa' -was a lot easier than it is today, with the myriad directions that this field has taken. Perhaps it would be safest to claim, as Professor Marvel told Dorothy in The Wizard of Oz, 'That's it -the crystal's gone dark'. Twentyfive years after our 1992 review, there are reasons to be less sanguine about the utility of PPI as a tool to understand the neural circuit disturbance in psychopathology.
First, it has become clear over the past 25 years that the neuropathology of many brain disorders -and schizophrenia is a prime example -is widely distributed throughout different levels of CSPT circuitry, and highly heterogeneous across patients (see Swerdlow, 2011) . Even a high resolution 'pontine portal' cannot provide the level of anatomical resolution needed to generate an orderly map of such variable and dispersed neural disturbances. Second, specifically because PPI is regulated by circuitry thatin its essence -defines much of what constitutes the complex, variable and individualized features of human consciousness, studies over the past 25 years have shown that PPI is very sensitive to a long list of 'individualizing' factors, even within healthy populations. These factors include subject demographics (age, sex, race), state-defining normal physiological variables (reproductive hormones, stress, fatigue, resting blink rate), substance use (smoking), more complex variables such as personality, and a long list of experimental parameters and conditions that require substantial oversight (reviewed in Swerdlow et al., 2008) . Even with the strictest inclusion/exclusion criteria for clinically impaired and healthy comparison populations, using PPI to characterize circuitry differences between these populations -particularly in an era with increasingly sophisticated and accessible neurophysiological and brain imaging tools -may not be the best use of this reflex measure.
On the other hand, there are many new uses of PPI that are indirectly related to its underlying neural circuitry, which we did not anticipate at the time of our 1992 paper, and which may represent future 'growth areas' for this science. First, PPI has had increasing use as an 'endophenotype' to identify risk genes and polygenic risk load in clinical populations (especially schizophrenia, e.g. Greenwood et al., 2012 Greenwood et al., , 2013 , and -in concert with other quantitative physiological and neurocognitive measures -it may ultimately serve this role for disorders other than schizophrenia.
Second, there is increasing evidence that PPI -perhaps as a marker of 'intact' CSPT resources in clinical populations -may be useful as a biomarker predicting clinical response to therapies ranging from cognitive behavioral therapy (Kumari et al., 2012) to stimulants (Swerdlow et al., 2013 (Swerdlow et al., , 2016 . We have written previously that 'biomarkers of spared function' rather than 'biomarkers of disease' can be the strongest predictors of a positive therapeutic response to various clinical interventions (Light and Swerdlow, 2015) . In a simple model, 'healthier' (higher) levels of PPI, for example, suggest the integrity of CSPT circuitry that can serve as a neural resource for neuroplasticity-based gains and their augmentation by medications. Ironically, the strategy of targeting healthy neural/psychological resources in order to correct disease-based deficits has been a longstanding tenet of interventions ranging from psychodynamic psychotherapy to stroke rehabilitation, yet it departs significantly from the failed strategy of trying to use drugs to 'undo' the neuropathology of schizophrenia that has dominated the past 60 years of schizophrenia psychopharmacology. Perhaps measures of 'healthy' CSPT function, such as PPI, will serve more prominent roles as predictive biomarkers in future treatment models for brain disorders.
Conclusion
The PPI literature has grown dramatically since the publication of our 1992 review, adding about one new PPI-related paper every 3.25 days during this time. Our review focused on the inter-relationships between: (a) disorders characterized by deficiencies within a domain of automatic inhibitory 'gating' processes; (b) PPI deficits among patients with these disorders; and (c) a limbic CSPP circuitry that we proposed might regulate PPI in rodents and humans, and might be central to the pathophysiology of 'gating' disorders in humans. Our speculation was based on very thin empirical data, but within those faint, tentative pencil strokes seems to have been a reasonable hint of the complex portrait that has emerged from 25 years of intensive investigation across our field. How to use this now mature body of empirical science to actualize its goal -to relieve suffering in individuals afflicted with mental illnessremains a major unanswered challenge for our field.
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Introduction
Several neuropsychiatric disorders are linked by deficiencies in the ability to suppress or 'gate' irrelevant or intrusive sensory, motor or cognitive phenomena. This review will focus on the use of a simple behavioral measure-the startle reflex-to study the brain mechanisms responsible for sensorimotor gating. Evidence is presented suggesting that 'gating' processes are controlled by neural interactions between the limbic system and basal ganglia. By studying the neurochemical and neuroanatomical substrates of sensorimotor gating of the startle reflex, we may gain insight into the pathophysiology of several forms of mental illness.
The startle reflex and pre-pulse inhibition The startle reflex is a contraction of the skeletal or facial muscles in response to an abrupt, intense sensory stimulus. For > 50 years, this reflex has been the focus of numerous investigations, punctuated in 1982 by the report of Davis and colleagues of a 'primary' mammalian acoustic startle circuit (Davis et al., 1982) . This circuit consists of four synapses linking the auditory nerve with the spinal motor neuron (Fig. 1 ). Davis (1980) has reviewed several features that make the startle reflex ideal for studies of the neural control of simple behaviors. Two features are particularly relevant to this discussion. First, startle can be measured automatically in humans and rats using identical stimulus parameters. Thus, this behavior can be reliably quantified and compared across species. Second, while the 'primary' control of the startle reflex involves brain structures at, or below, the level of the mesencephalon, the startle reflex exhibits several forms of plasticity that appear to be mediated by 'higher' brain regions. One form of this plasticity is 'pre-pulse' inhibition' (PPI) which is the normal suppression of the startle reflex when the intense startling stimulus is preceded 30-500 ms earlier by a barely detectable pre-stimulus (Graham, 1975) (Fig. 2) . In PPI, a weak pre-pulse activates mechanisms that inhibit a reflex response to a powerful sensory stimulus. Figure 1 The 'primary startle circuit', updated from Davis et al. (1982) . This circuit consists of four synapses: auditory nerve; 1, posterioventral cochlear nucleus; 2, ventral nucleus of the lateral lemniscus; 3, nucleus reticularis pontis caudalis; 4, spinal motor neuron PPI occurs in several sensory modalities, and in several species including humans. It is not a form of conditioning-it occurs on the first exposure to the pre-pulse and pulse stimuli, and it does not exhibit habituation or extinction. The interval between pre-pulse and pulse (typically 100 ms) is too short to evoke conscious voluntary behavioral inhibition. PPI thus appears to reflect the activation of powerful 'hard-wired' centrally mediated behavioral 'gating'. The inhibitory processes activated by the weak 'pre-pulse' and the resulting decrement in startle amplitude have been used in an Figure 2 Pre-pulse inhibition is a profound decrease in startle amplitude when the startling 'pulse' is preceded by a weak acoustic 'pre-pulse'. The degree of pre-pulse inhibition is expressed as: operational definition of sensorimotor gating: the degree to which a startle reflex is inhibited by a pre-pulse is a measure of the amount of sensorimotor gating.
Gating deficits in neuropsychiatric disorders?
Several neuropsychiatric disorders are characterized by a loss of the normal ability to suppress or 'gate' intrusive or irrelevant sensory, motor or cognitive information. This loss of 'gating' may be experienced as intrusive thoughts, sensory information or adventitious movements or behaviors. For example, schizophrenic patients are often unable to suppress or 'gate' irrelevant thoughts and sensory stimuli from intruding into consciousness, and patients with obsessive-compulsive disorder (OCD) are unable to suppress intrusive obsessions. Deficient gating of involuntary vocalizations and tics occurs in Tourette's s syndrome, and deficient suppression of adventitious movements is seen in patients with Huntington's disease (HD). Thus, a wide range of disorders are linked phenomenologically by a deficient capacity to 'gate' or suppress sensory, cognitive or motor processes. It might be possible to study the brain substrates of defective gating in several disorders by designing separate measures of gating that are appropriate for each specific disorder. This strategy would require several different indices of suppression of sensory information, thoughts, movements or behaviors, and each would require a separate analysis of gating deficiencies on phenomenological and anatomical levels. Alternatively, it might be possible to identify a single measure of fundamental gating mechanisms. Such a 'unitary' measure of gating processes might be better suited for systematic study in several different disorders at phenomenological and anatomical levels. PPI of the startle reflex might be an ideal candidate for such investigation, since it is a measure of sensorimotor gating that is suitable for multiple levels of neural analysis in humans and in animal models.
For PPI to be a useful measure of sensorimotor gating in neuropsychiatric disorders, it should satisfy several criteria. Among these, PPI should be impaired in disorders that are clinically characterized by deficient cognitive or sensorimotor gating. Further, PPI should be modulated by discrete neural substrates that are relevant to the pathophysiology of these disorders.
Sensorimotor gating deficits have been quantified in schizophrenic patients using the startle reflex.
Schizophrenics have deficient PPI, and exhibit a startle reflex that is not fully 'gated' by the acoustic pre-pulse . Recent studies have replicated this finding in a larger sample of patients [Braff, Grillon and Geyer, 1991; Grillon, Ameli and Braff, 1991; (submitted)], and have revealed that PPI deficits may correlate with other cognitive abnormalities in these patients. For example, gating of tactile (air-puff) startle is significantly more impaired in schizophrenic patients who perform poorly on the Wisconsin card sorting test (WCS) than in matched patients who are not as deficient in the WCS measure . PPI is also deficient in patients with 'schizophrenic-spectrum' disorders, including schizotypal personality disorder (Simons, 1990) . In addition, our preliminary findings (below) suggest that PPI is impaired in patients with Huntington's disease (Swerdlow et al., 1990c) , and sensorimotor gating deficits have also been measured in patients with Tourette's syndrome, using a similar pairedstimulus blink paradigm (Smith and Lees, 1989) . Thus, gating processes that are measured by PPI may be impaired in schizophrenic, schizotypal and Huntington's disease patients, and related processes may be impaired in patients with Tourette's syndrome. PPI appears to be a simple quantifiable measure of sensorimotor gating that is phenomenologically similar to processes of behavioral or cognitive suppression, and has been shown to be impaired in disorders of deficient gating of undesired sensory stimuli, thoughts and behaviors.
Pharmacology and anatomy of pre-pulse inhibition Motivated in part by the observation of deficient startle 'gating' in schizophrenic patients, several investigators have studied the neural substrates that modulate pre-pulse inhibition of the startle reflex in rats and in humans. As reviewed below, these studies have begun to identify neural circuitry linking the limbic system and basal ganglia that modulate PPI and that may be critical substrates responsible for deficient sensorimotor gating in certain neuropsychiatric disorders.
Pharmacology of PPI

Dopamine
Several studies suggest that brain dopamine (DA) systems are critical substrates for sensorimotor gating of the startle reflex. In rats, PPI is reduced by drugs that facilitate brain DA activity, including the DA agonist apomorphine (APO) (Swerdlow et al., 1986 and the indirect DA agonists D-amphetamine (AMPH) Swerdlow et al., 1990a) , and cocaine (R. Mansbach and M. Geyer, unpublished observation), and these effects are reversed by DA receptor antagonists Swerdlow et al., 1991a) . The AMPH-induced disruption of PPI is evident after both acute and chronic administration , and startle gating is also reduced by substituted congeners of methamphetamine, MDMA and MDEA . The effects of APO on PPI are evident for both acoustic and tactile startle at low doses-0.25-0.4 mg/kg subcutaneously (s.c.)-that do not produce overt behavioral activation, while the effects of AMPH on PPI are most evident at relatively higher doses-1.0-2.0 mg/kg s.c.that do produce behavioral activation (Swerdlow et al., 1986 (Swerdlow et al., , 1990a . While higher doses of both APO and AMPH have been reported to increase startle reflex amplitude, the effects of DA agonists on PPI are independent of changes in baseline reflex amplitude. For example, low doses of APO that have no significant effect on startle amplitude virtually eliminate PPI (Swerdlow et al., 1986 , while drugs that significantly potentiate startle amplitude (e.g. strychnine; M. A. Geyer, manuscript in preparation) or depress startle amplitude (e.g. haloperidol; do not decrease PPI. These observations suggest that separable neural substrates are Figure 3 Pre-pulse inhibition in normal controls and schizophrenic patients. (A) PPI of acoustic startle as measured in potentiometric studies of the eyeblink component of startle Further evidence that brain DA activity modulates PPI comes from studies by Schwartzkopf, Bruno and Mitra, (1990) , in which neonatal rat pups received intraventricular infusions of the catecholamine neurotoxin 6-hydroxydopamine (60HDA) to deplete DA from the entire brain. This preparation is known subsequently to potentiate the behavioral effects of direct DA agonists when rats are tested as adults. DA-lesioned rats showed an increased sensitivity to the PPI-disruptive effects of low doses of APO, compared to rats that had received intra-ventricular saline infusions as pups. Thus, PPI is disrupted by APO in intact animals, and this effect is enhanced by whole-brain neonatal DA lesions that increase behavioral sensitivity to DA agonists.
Another drug that disrupts PPI is the psychotogen lysergic acid-diethylamide (LSD). The psychotomimetic effects of LSD have been used in both animal and human models of symptoms related to the group of schizophrenic disorders. While LSD has both DAergic and serotonergic properties, the effects of LSD on PPI are reversed by the DA antagonist haloperidol, but not by the 5-HT2 2 antagonist ritanserin . Thus, the LSD-induced disruption of PPI may be mediated via DAergic substrates.
Studies have revealed that the DAergic modulation of PPI is dependent on both stimulus parameters and animal strain. Thus, Davis et al. (1990) reported that APO disrupts PPI when the pre-pulse stimulus is weak (e.g. 10 dB greater than background noise), but not when the pre-pulse stimulus is intense (e.g. 30 dB greater than background noise). These investigators suggested that APO may impair PPI by disrupting the ability of rats to detect the weaker pre-pulse stimulus. Other studies have reported that APO disrupts PPI in Wistar rats even when stronger pre-pulse intensities are used, while APO does not disrupt PPI in CD (Sprague-Dawley derived) rats even when only weak pre-pulses are used ). These reports suggest that both stimulus-parametric and genetic (strain-based) strategies might provide meaningful information regarding the DAergic modulation of sensorimotor gating in rats.
Of the two major classes of DA receptors, the D2 receptor may mediate the APO disruption of PPI, since this effect of APO is blocked by the D2 antagonists raclopride and spiperone, but not by the D antagonist SCH 23390 . Further support for a primary role of the D2 receptor, but not the D 1 receptor, as a substrate of DA agonist-induced changes in PPI is the finding by Peng et al. (1990) that PPI is disrupted by the D2 agonist quinpirole, but not by the D 1 agonist SKF 38393. These effects of quinpirole are reversed by the DA receptor antagonist haloperidol . Interestingly, PPI is also disrupted by high doses of (Swerdlow et al. , 1991 a) . Our studies in progress are examining the interactions of D 1 and D2 mechanisms in the modulation of PPI.
A summary of representative findings from our laboratory that are related to the DAergic modulation of PPI is seen in Fig. 4 .
The ability of DA antagonists to 'normalize' startle gating in APO-treated animals may ultimately serve as a useful screening method for drugs with antipsychotic potential. Thus, antipsychotics that reverse the APOinduced loss of PPI include haloperidol Swerdlow et al., 1991 c) , spiperone, raclopride (Swerdlow et al., 1991 a) , prochlorperazine, chlorpromazine, perphenazine (Swerdlow et al., 1992a) and risperidone (Rigdon and Viik, 1991) , as well as the atypical antipsychotic clozapine, which lacks neuroleptic properties in some behavioral assays . While the clinical potencies of raclopride and risperidone are not certain, the antipsychotic potencies of the remaining six drugs in Table 1 correlate significantly with their ability to reverse APO-disrupted PPI. To date, no drug with antipsychotic properties has failed to reverse this APO effect; in contrast, psychotropic drugs that fail to reverse the APO-induced loss of PPI include imipramine, Table 1 Dose of antipsychotic required to maximally reverse APO-disrupted PPI in rats (mg/kg s.c.) and average daily dose for treating schizophrenia (~mol/kg) *Rl for known values = 0.95, p < 0.05 diazepam and buspirone (Rigdon and Viik, 1991) , all of which lack antipsychotic properties. Given the small number of compounds tested, we can only speculate that the ability of a drug to 'normalize' gating in APO-treated rats may meet several important requirements of drug screening models: (1) it is specific, i.e. it identifies only drugs with antipsychotic potencies; (2) it is predictive of their relative clinical potencies; (3) it is sensitive to low doses of drugs, and to drugs with relatively low potencies (e.g. chlorpromazine and clozapine); and (4) it is selective, i.e. does not falsely identify psychotropic compounds that lack antipsychotic potency. Glutamate Brain glutamate systems have been implicated in the modulation of PPI. PPI is disrupted in rats by drugs that block transmission at the N-methyl-D-aspartate (NMDA) receptor complex, including the non-competitive NMDA antagonists phencyclidine (PCP) and dizocilpine (MK-801) . While PCP is also known to augment DA transmission, the effects of PCP on PPI are not reversed by haloperidol and thus are not likely to reflect its DA agonist properties . Interestingly, the PPIdisruptive effects of non-competitive NMDA antagonists are not shared by competitive NMDA antagonists, including NPC 12626 and CGS 19755 (Mansbach, 1990) .
Acetylcholine
The cholinergic modulation of startle is unclear (Davis, 1980) . In rats, dietary restriction of choline-an essential precursor of acetylcholine (ACh)-results in a potentiation of startle amplitude (Newton, Crossland and Jenden, 1986) . It was recently reported that similar dietary restriction of choline in rats also reduces levels of PPI (Wu, M. F. et al., 1990 ), suggesting that intact brain cholinergic activity is required for normal startle gating. In other studies (discussed below), intra-hippocampal infusion of cholinergic agonists markedly disrupts PPI, suggesting that increased regional ACh activity can actually impair startle gating. Since the effects of hippocampal manipulations of brain ACh on PPI seemingly conflict with the gating effects of dietary choline restriction, a full analysis of regional ACh activity will probably reveal heterogeneity in the cholinergic substrates of PPI.
Opiates
Brain opiate systems are thought to be critical substrates of several important behaviors in rats, and may modulate the effects of other brain transmitters on behavior. For example, opiates may play a 'permissive' role in the behaviorally activating effects of forebrain DA release in the rat, since the behavioral activation produced by indirect, but not direct, DA agonists is reversed by naloxone-induced opiate receptor blockade (Swerdlow et al., 1987) . Similar processes may underlie an opiate modulation of PPI. Thus, naloxone reverses the disruption of PPI produced by the indirect DA agonist AMPH, but does not reverse the disruption of PPI produced by the direct DA agonist APO (Swerdlow et al., 1991 b) . This finding suggests that DA mechanisms that control PPI are under the pre-synaptic regulation of opiate receptors, and that blockade of these opiate receptors prevents the expression of these DAergic effects. While opiates may play a modulatory role in the expression of PPI, there is evidence against a more direct opiate regulation of PPI, since the opiate heroin-at doses ranging from behaviorally activating to sedating (Amalric and Koob, 1985) -has no significant effect on PPI .
Anatomy of PPI The hippocampus (HPC)
Sensory gating of auditory evoked potentials can be recorded in hippocampal neurons in rats (Bickford-Wimer et al., 1990) . A role for the HPC in modulating PPI is suggested by our findings that PPI is blocked by intra-HPC infusion of carbachol (Caine, Geyer and Swerdlow, 1991a) , but not by 'control' infusions of carbachol into parietal cortex. Intra-HPC carbachol infusion disrupts PPI of both acoustic and tactile startle, suggesting that the HPC modulation of PPI is not modality specific (Caine, Geyer and Swerdlow, 1991 a) .
The effects of carbachol on PPI are most evident after infusion into the dentate gyrus or region CA1, and are weaker-though statistically significant-after infusion into the ventral subiculum. These effects of carbachol are likely to be specific to its properties as a cholinergic agonist, since they are reversed by concomitant administration of the anticholinergic atropine .
Intra-HPC carbachol infusions may impair PPI by stimulating glutamate release in the nucleus accumbens (NAC) via HPC-NAC glutamate fibers. Such a mechanism is suggested by our preliminary finding that PPI is disrupted by intra-NAC glutamate infusion (Swerdlow et al., 1991d) , and by reports that intra-HPC carbachol infusions cause behavioral activation that is blocked by intra-NAC infusion of glutamate antagonists (Mogensen and Nielsen, 1984) .
While HPC-NAC efferents may be critical substrates for this effect of HPC carbachol infusion on PPI, these effects appear to 'bypass' NAC DA receptors, since they are not reversed by the D2 antagonist spiperone in doses that block the PPI-disruptive effects of APO. A Figure 5 PPI in rats after carbachol infusion into the HPC (A-D) or parietal cortex (E), or after glutamate infusion into the NAC (F). Intra-HPC carbachol disrupts PPI of acoustic startle (A) and tactile startle (B); this effect is blocked by coadministration of atropine into the HPC (C), but not by D2 blockade with spiperone (D). Carbachol infused into parietal cortex does not decrease PPI (E). Glutamate infusion into the NAC does impair PPI (F). See text for discussion summary of findings from our laboratory that are related to the hippocampal modulation of PPI is seen in Fig. 5 .
The nucleus accumbens (NAC)
The NAC receives converging fibers from limbic areas, including the amygdala, hippocampus and cingulate gyrus, and from midbrain DA cells in the ventral tegmentum (Nauta et al., 1978; Heimer et al., 1987) .
Several studies suggest that the NAC is a critical substrate of PPI, and that the effects of DA agonists on PPI are mediated by increased DA activity in the NAC. First, startle gating produced by pulsing tactile stimuli is eliminated by electrolytic lesions of the NAC (Sorenson and Swerdlow, 1982) . Second, low doses of APO that do not decrease PPI in intact rats potently disrupt PPI in rats that are surgically altered to have 'supersensitive' DA receptors in the NAC after NAC infusions of 60HDA (Swerdlow et al., 1986) . These effects are maximal at short pre-pulse intervals (60ms), and are not evident in animals that receive 60HDA infusions into the frontal cortex (Swerdlow et al., 1986) . Third, the loss of PPI induced by the indirect DA agonist AMPH is reversed by depletion of DA in the NAC (Swerdlow et al., 1990a) ; depletion of NAC DA does not, however, reverse the AMPH-induced increase in startle reflex amplitude. Fourth, PPI is disrupted in rats by intra-NAC DA infusion (Swerdlow et al., 1990b) , and this loss of PPI follows the same time-base (pre-pulse-pulse intervals < 500 ms) as the APO-induced loss of PPI in rats. Thus, the NAC is one of the critical loci of DAergic control of PPI and sensorimotor gating. A summary of representative findings from our laboratory that are related to the nucleus accumbens DAergic modulation of PPI is seen in Fig. 6 . Additional studies suggest that DA activity in areas other than the NAC might modulate sensorimotor gating in the rat. First, PPI is disrupted by low doses of APO in rats that have surgically induced 'supersensitive' DA receptors in the caudate-putamen (Swerdlow et al., 1986) . In contrast to the APO-induced effects in NAC 'supersensitive' animals, these effects after striatal 60HDA infusions are most evident at longer (120 ms) pre-pulse intervals. Second, intra-NAC DA infusions disrupt PPI far less than do peripherally administered DA agonists (Swerdlow et al., 1990b ), suggesting that NACDA overactivity alone cannot account for the PPI deficits produced by systemic DA agonists. Finally, our recent findings indicate that DA infusion into the anteromedial striatum significantly disrupts PPI. In contrast, DA infusion into the posterior striatum, orbital cortex or amygdala centralis does not significantly impair PPI . Figure 7 Pre-pulse inhibition of acoustic and tactile startle in controls and patients with HD. Groups do not differ significantly in age, sex or startle reactivity. *p < 0.05, t-test following significant ANOVA. D control (n = 19) N HD (n = 9) (manuscript in preparation).
Preliminary work in our laboratory suggests that pathology in the dorsal striatum may disrupt PPI in humans. Huntington's disease (HD) is characterized by a loss of Spiny I GABAergic cells that form the striatopallidal efferent projection. Work in progress suggests that HD patients show deficient PPI (Swerdlow et al., 1990c) . PPI deficits in HD patients are evident at all prepulse intervals tested (30-120 ms), and in both acoustic and tactile startle modalities (Fig. 7) . HD patients appear to show normal levels of baseline acoustic and tactile startle amplitude, but demonstrate a marked slowing of reflex onset and peak amplitude (Swerdlow et al., 1990c) . Both the loss of PPI and the increased reflex latency in HD patients correlate significantly with their age; since no such correlations are found in age-matched control subjects, it is possible that these changes in startle gating and latency reflect a progression of the disease process in HD patients (Swerdlow et al., 1990c) . NAC-ventral pallidum GABAergic projection _ Findings in our laboratory suggest that decreased PPI after NAC DA activation might reflect decreased activity in GABAergic fibers projecting from the NAC to the ventral pallidum (VP). The PPI-disruptive effects of NAC DA infusion in rats are reversed by infusion of the GABA agonist muscimol into the VP, and are reproduced by intra-VP infusion of the GABA antagonist picrotoxin (Swerdlow et al., 1990d) . This NAC-VP GABAergic projection is a substrate for other behavioral effects of NAC DA activation Koob, 1985, 1987b; Mogenson, 1987) , and is thought to translate the effects of activity in the amygdala and HPC to lower motor circuitry (Mogenson and Nielsen, 1984; Mogenson, 1987) . A summary of representative findings from our laboratory that are related to the role of the NAC-VP GABAergic projection in the modulation of PPI is seen in Fig. 8 . Figure 8 Pre-pulse inhibition of acoustic startle in rats following manipulations of nucleus accumbens DA and ventral pallidal GABA activity. Data compiled from several studies (see text). (A) Infusion of the GABA agonist muscimol into the VP reverses the decrease in PPI caused by intra-NAC DA injection. (B) Infusion of the GABA antagonist picrotoxin into the VP causes a dose-dependent decrease in PPI. *p < 0.05 difference from 0 p.g dose DA (A) or picrotoxin (B)
Ventral pallidal efferents to the pedunculopontine nucleus Ventral pallidal efferent projections include fibers that terminate in the dorsomedial nucleus of the thalamus (DMT) and others that terminate within the pedunculopontine nucleus (PPN) in the pontine reticular formation. These VP projections have both been implicated as substrates for the behavioral expression of mesolimbic DA activity in studies employing measures of locomotor activity (Swerdlow and Koob, 1987b) , food hoarding (Mogenson and Wu, 1988) , intravenous cocaine self-administration (Hubner and Koob, 1988 ) and place conditioning (Bechara and van der Kooy, 1989) . Both projections are believed to be GABAergic, based on immunohistochemical and electrophysiological evidence (Swanson et al., 1984; Vives and Mogenson, 1985) . VP infusions of picrotoxin activate these GABAergic projections and impair PPI, presumably via a GABA-mediated cellular inhibition in either the DMT, PPN, or in both regions. In a preliminary study of the role of these VP efferents in startle gating, we measured PPI in rats after electrolytic lesions of either the PPN or DMT. Lesions of the PPN-but not the DMTdramatically disrupt PPI (Fig. 9 ) (Swerdlow et aL, 1991c) . These PPN lesions are immediately adjacent to the nucleus reticularis pontis caudalis (NRPC), which is the site of the 'third synapse' in the startle circuitry described by Davis et al. (1982;  Fig. 1 ). Importantly, these PPN lesions do not appear to impinge directly on the NRPC, since lesions of the NRPC abolish the startle reflex (Davis et al., 1982) , while PPN lesions actually enhance startle amplitude (Swerdlow et al., 1991c) . VP efferents to the PPN appear to link limbic system and basal ganglia circuitry that modulates sensorimotor gating with Figure 9 PPI in rats after electrolytic lesions of the dorsomedial thalamus (n = 9), pedunculopontine nucleus (n = 10) or sham lesions (n = 10). Sham group consisted of five animals with sham lesions from each of the two locations. *p < 0.05 by t-test after significant effect of lesion group by ANOVA. Lesions of the PPN also significantly increase startle reflex amplitude (not shown) reticular formation structures that are the 'primary' circuitry for the startle reflex. Summary: limbic system-basal ganglia substrates of sensorimotor gating of the startle reflex These results give initial support for the role of limbic system and basal ganglia interactions in deficits of sensorimotor gating of the startle reflex in rats (Fig. 10 ). PPI is decreased by carbachol infusion into the HPC; this decrease in PPI results from activation of cholinergic receptors in the HPC and may reflect the activation of glutamate efferents to the NAC. PPI is also decreased by D2 activation of the ventral striatum, apparently via a decrease in GABA release in the VP. These results, together with previous reports , are consistent with the hypothesis that sensorimotor Figure 10 Brain circuitry proposed to be substrates of sensorimotor gating in rats. This circuitry includes limbic glutamate-and mesolimbic dopamine-innervation of the NAC, NAC GABAergic efferents to the VP and VP efferents to the pedunculopontine nucleus. This VP-PPN projection is thought to be GABAergic, and may link limbic and striatal structures with mesencephalic components of the 'primary startle circuit' 'gating' deficits in schizophrenic patients and possibly HD reflect a loss of normal neural interactions between limbic structures such as the hippocampus and basal ganglia circuitry linking the striatum and pallidum.
Are these substrates relevant to disorders of deficient cognitive or sensorimotor gating?
Evidence for dysfunction in limbic system and basal ganglia circuitry in several neuropsychiatric disorders ranges from clinical observations to data from electrophysiological, neurochemical and neuropathological studies ( Table 2 ). The emergent theme from this literature is that several disorders are linked in a phenomenological dimension by an inability to 'gate' undesired thoughts or behaviors, and are also linked in a neuroanatomical dimension by a loss of normal interactions between Table 2 Limbic cortex and basal ganglia (LC/BG) dysfunction and deficient cognitive and sensorimotor gating in several disorders VBM = visual backward masking; OCD = obsessive-compulsive disorder; HD = Huntington's disease; PFC = pre-frontal cortex; HPC = hippocampus; ERP = event-related potential; TS = Tourette's syndrome.
cortical and subcortical components of limbic systembasal ganglia (LC/BG) circuitry. Since related circuitry appears to modulate 'gating' of the startle reflex, the anatomical substrates of PPI may be relevant to the pathophysiology of deficient sensorimotor gating in several neuropsychiatric disorders. The importance of this LC/BG circuitry in understanding several psychiatric disorders has been discussed in the context of a heuristic model of cortico-striatopallido-thalamic dysfunction (Swerdlow and Koob, 1987a) . While pathology in individual components of this circuitry has been implicated in several disorders, the functional interconnections and infrastructure of these brain regions-as demonstrated partially in the pre-clinical studies discussed above-suggests that gating-related neuropsychiatric disorders might best be conceptualized as disorders of a dysfunctional neural 'circuit', or 'network', rather than disorders caused by an isolated brain 'lesion'. One implication of this view is that a single class of gating-related psychopathologies-for example, the schizophreniasmight reflect dysfunction at one or multiple different levels of LC/BG circuitry. Consequently, pharmacologic strategies for 'normalizing' gating circuit function might be aimed at any one of several levels of this same circuitry. For example, our findings suggest that gating-related disorders caused by a primary dysfunction within the HPC might not be fully responsive to DA receptor antagonists, but might instead be treated best with drugs aimed 'beyond' the DA receptor-that is, at NAC glutamate receptors, or perhaps ventral pallidal GABA receptors. While the practical utility of this strategy remains limited by the availability of selective pharmacological agents, Figure 11 (A) APO-treated rats exhibit no PPI, but still show significant latency facilitation. Thus, the APO-induced loss of PPI cannot simply reflect a loss of pre-pulse 'detection', since in these same animals, the pre-pulse causes a significant behavioral change (latency facilitation). Data extracted from Swerdlow et al. ( 1991 a) . (B) Peak startle latencies in normal controls and patients with Huntington's disease, from data displayed in Fig. 7 . As previously discussed, HD patients exhibit significantly less PPI than ageand sex-matched controls. Startle latencies are also significantly increased in HD patients compared to controls at all pre-pulse conditions. Despite markedly impaired startle gating in these patients, they exhibit normal amounts of latency facilitation at 30, 60 and 120 ms pre-pulse intervals. Thus, as noted in (A), this loss of PPI cannot simply reflect a loss of prepulse 'detection'. Data from Swerdlow et al. (1990c) . *significant main group effect by ANOVA (HD versus CNTL); # significant decrease from 0 ms condition by t-test after significant effect of interval by ANOVA. Group x interval effect was not statistically significant (F < 1) (manuscript in preparation). this same strategy applied to pre-clinical models might facilitate such drug development.
Pre-clinical implications of the neural substrates of startle gating
In addition to the potential clinical implications of this 'gating circuitry', there are several important pre-clinical issues related to startle gating that deserve attention. First, the psychophysiological mechanisms of the modulation of PPI must be clarified. If a loss of PPI reflects a change in the 'detectability' of the pre-stimulus-as suggested by Davis et al. (1990) -then this implicates a modulation of gating within circuitry integrally involved in sensory processing. Such a modulation would require complex and redundant neural circuitry: since PPI occurs in several sensory modalities, a mechanism for modulating pre-pulse 'detectability' would be needed within each different modality. Furthermore, if a loss of PPI reflects a decreased 'detection' of the pre-pulse, then other behavioral phenomena mediated by the pre-pulse should similarly be disrupted. Several findings suggest, however, that even in conditions where PPI is markedly impaired-for example, in patients with schizophrenia (Braff, Grillon and Geyer, 1991 ) or Huntington's disease (Swerdlow et al., 1990c) , or in APO-treated rats (Swerdlow et al., 1991 a) -the effects of the pre-pulse on reflex latency ('latency facilitation') remain intact (Fig. 11) . Thus, the disruption of PPI occurs despite the fact that the pre-pulse is clearly detected and is behaviorally influential. It is also possible that a loss of PPI reflects a decreased influence of the pre-stimulus on cellular activity within the 'primary' startle circuit. Such mechanisms should be sensitive to conditions that alter basal levels of reactivity, and thus potentiate or depress baseline reflex amplitude.
However, as discussed above, the modulation of startle gating and startle reactivity can be dissociated by drugs, lesions and stimulus parameters. Alternatively, a loss of PPI might result from a decrease in more centrally located inhibitory mechanisms; such a loss of central inhibition would impinge onto primary 'effector' circuitry, including primary startle circuitry as well as cortical substrates of cognition, and thus modulate 'gating' of a wide range of sensory, motor or cognitive processes.
Second, the neurophysiological mechanisms of the modulation of PPI must be clarified. Thus, it is important to study the specific cellular interactions of descending forebrain modulatory circuitry and the 'primary' startle circuit. These interactions are important in understanding the pathophysiology of disorders characterized by abnormal startle gating-such as schizophrenia-and these interactions may also be physiological 'models' for processes that occur at the junctions between forebrain modulatory circuitry and other 'effector' circuitry responsible for the gating of more complex cognitive and behavioral processes. Since PPI occurs at latencies as short as 15 ms in rats (Hoffman and Searle, 1968) , it is likely that the modulation of the inhibitory effects of the pre-stimulus occurs within, or near, the primary startle circuitry (Fig. 12 ). These effects are long-lasting rather than phasic or stimulus-bound, and thus it is possible that they are ultimately mediated via peptidergic systems capable of maintaining a sustained neural 'tone'. Such a peptidergic modulation of 'primary' startle circuitry has been implicated in the potentiation of startle by stress or fear (Hitchcock and Davis, 1986) . Based on our findings described above, one might predict that such an inhibitory influence would originate in or near the PPN and would innervate the NRPC.
Finally, the psychological implications of the modulation of PPI must be considered. The functional 'utility' of gating mechanisms has been discussed from a theoretical basis , in which the inhibitory mechanisms activated by a weak pre-stimulus suppress the behavioral and cognitive 'impact' of stronger stimuli received in the subsequent 500 ms period and thus prevent Figure 12 Schematic diagram for three known temporal parameters of PPI of acoustic startle in rats. The startle reflex latency, from stimulus onset to hindleg EMG activation, is 8 ms. The inhibitory effects of the weak pre-pulse have a latency of -15 ms, and these inhibitory effects last -500 ms 'flooding' or overload of cognitive information and a consequent fragmentation of behaviors or thoughts. In this view, gating mechanisms are protective of discrete bits of information that are salient above background 'noise' levels, and since this gating occurs tonically-rather than in artificial 'bursts' used in a laboratory setting-it protects continuity of thought or action and prevents rapid cognitive and behavioral 'switching'.
Based on the neural substrates discussed above, it is possible to speculate further regarding the psychological 'utility' of the modulation of gating mechanisms. There appears to be substantial overlap between brain substrates that mediate sensorimotor gating in the rat and substrates that mediate several endogenous 'goal-seeking' or appetitive behaviors, including locomotor activity (Roberts, Zis and Fibiger, 1975) , rearing and sniffing (Koob et al., 1978) and food hoarding (Kelley and Stinus, 1985) , as well as reinforcement-seeking behaviors such as electrical brain stimulation (Koob, Balcolm and Meyerhoff, 1976 ) and
intravenous self-administration of psychostimulants (Lyness, Friedle and Moore, 1979) . Specifically, drugs that facilitate these appetitive behaviors-including DA agonists-generally disrupt startle gating, and drugs that impair the reinforcing or activating effects of DA agonists generally reverse the gating effects of these drugs. There are some notable exceptions to this association: heroin, which stimulates behavioral activation and potently sustains motivated behaviors (Bozarth and Wise, 1981; Amalric and Koob, 1985) has no consistent effect on startle gating . Nonetheless, it is possible that the overlap in DAergic mechanisms of reinforcement and sensorimotor gating parallels an integral relationship of these processes at a psychological level. Thus, decreased sensorimotor gating during forebrain DA activation may modify the initiation and organization of appetitive behaviors by allowing increased amounts of sensory information to activate lower motor structures. The behavioral response to a salient sensory cue might normally be gated or suppressed by a previous weak stimulus that occurs within a contiguous 500 ms period; in the presence of increased mesolimbic DA activity, this gating is diminished, and the behavior directed by the more salient cue should be enhanced. Since the cortical efferents to the ventral striatum originate primarily within the limbic system (Nauta et al., 1978) , the sensory information that may be most sensitive to this gating process should be of visceral or affective valence. Thus, the overlap in limbic and basal ganglia substrates of reinforcement and sensorimotor gating may reflect the fact that changes in gating circuit activity ultimately regulate the extent to which particular appetitive cues elicit or shape goalseeking behaviors. In other words, DA-linked reinforcing stimuli may become salient in part by disrupting normal gating processes that would otherwise suppress their ability to direct a behavioral response. We currently are investigating the precise relationship between the DAergic substrates of reinforcement and sensorimotor gating.
Future directions for the study of sensorimotor gating of the startle reflex Future studies of the neural substrates of sensorimotor gating might include efforts in three directions. First, continued anatomic and neurochemical studies of the 'gating circuit' should focus on two circuit components:
(1) efferent projections from the hippocampus and other areas of limbic cortex and their synaptic interactions with striatal circuitry, and (2) the pallidal efferents that transmit information from the ventral striato-pallidal projection to the primary startle circuit. The latter studies might be facilitated by the use of electrically stimulated startle: by using an acoustic pre-pulse paired with an electric 'pulse', it would be possible to identify the site within the primary circuit where the inhibitory effects of the pre-pulse are expressed (Fig. 13 ). This approach is similar to that used by Davis et al. (1982) to define the 'primary' startle circuit, and assumes that at some site within the primary circuit the pre-pulse 'gates' the startling effects of the pulse. 'Distal' to this site, Figure 13 One strategy for identifying the site within the 'primary' startle circuit where the pre-pulse 'gates' the startling effects of the pulse. 'Distal' to this site, electrically induced startle should not be inhibited by the acoustic pre-pulse. A similar strategy was used by Davis et al. (1982) to identify the 'primary' startle circuit electrically induced startle should not be inhibited by the acoustic pre-pulse.
A second major direction of study should focus on the clinical implications of sensorimotor gating deficiencies. These studies might assess PPI in several psychiatric disorders in which the core symptoms reflect a loss of cognitive, motor or sensory gating, including schizophrenia, OCD, Tourette's syndrome and disorders of impulsivity and substance abuse. In addition to traditional approaches to such clinical studies-including measurements of state versus trait properties, family studies, medication/drug challenges and correlations with other neuropsychological indices-clinical studies of PPI should include extensive parametric manipulations that might identify specific forms of startle gating deficiencies that characterize different disorders or stages of illness. Such a 'fingerprint' analysis of critical pre-pulse intervals, intensities or modalities-when interpreted in the context of pre-clinical evidence for an anatomical basis for these patterns of PPI-might eventually reveal the anatomy of gating deficits in different psychiatric disorders.
It might ultimately be possible to localize neural dysfunction within gating 'circuitry' in different neuropsychiatric disorders through the use of computer-based circuit models. Thus, using pre-clinical data to construct simple diagrams of forebrain neuronal interactions-as described above (Fig. 10) -it is feasible to model the dynamic characteristics of this circuitry to predict the contribution of each circuit element to the behavioral measure of gating. Thus, based on the particular circuit interactions, each structure within the circuit will have a pattern of neuronal activity that can be described, in a very simplified model, by an equation that defines a probability distribution. By expressing the behavioral measure of gating for a given patient in similar probabilistic terms (e.g. the distribution of highly gated versus less gated responses), it might be possible to identify the relative contribution of each circuit element to their behavioral probability pattern, and to determine how this contribution changes with medication or drug challenges. Similar models for the dynamic analysis of biological systems have been applied to neural systems from the level of enzyme kinetics to that of exploratory locomotion (Paulus et al., 1990) . While the utility of this approach must ultimately be limited by the complexity of the circuit models and their anatomical accuracy, such modelling can at least be used to generate testable hypotheses that address dynamic relationships between brain substrates and gating patterns; i.e. how these relationships change when the circuitry is perturbed, and how they can best be restored to 'normal' function.
A third direction of study should focus on the neural substrates of other measures of sensorimotor gating. We have previously discussed the merits of some of these other measures (Swerdlow et al., 1988) , but two measures, latent inhibition (LI) and negative priming (NP), offer many advantages comparable to those of the startle response. Both LI and NP can be automated and studied across species using similar stimuli and designs, and thus both are suitable for the type of neuroanatomical and neuropharmacological analysis described above. Findings from several pre-clinical studies using LI suggest that the neural substrates responsible for the modulation of this 'gating' measure overlap at least somewhat with those discussed above, particularly within striatal DAergic mechanisms (Solomon and Staton, 1982) . By assessing gating substrates in several behavioral measures, it becomes less likely that consistent findings reflect peculiarities of any single measure, and thus the information gained from these studies can be more easily generalized to the clinical setting.
Conclusion
Reflex behaviors-such as the gill withdrawal reflex in Aplysia-have been used to identify the mechanisms of fundamental neuronal interactions in simple invertebrates. These studies benefit from the simple and definable anatomy and physiology that control the behaviors, and information generated from these studies is critical to our understanding of basic processes ranging from synaptic transmission to behavioral sensitization. Nonetheless, the relevance of this information to the pathophysiology of mental illness is not always obvious. More complex behaviors in rodents and primates have been used as models to study processes-such as drug selfadministration or social interactions-that are believed to closely parallel patterns of human behavior. The relevance of these infrahuman behaviors to human conditions is often quite apparent, but the complexities of these behaviors and their underlying anatomy and physiology, as well as the anthropomorphic assumptions inherent to their interpretation, can limit the utility of this approach for studying the neural substrates of psychopathology. It may be possible to extract the benefits of these two different approaches by using reflex behaviors in rodents and humans to study basic neuronal mechanisms that mediate simple behaviors in humans; this has been the aim of studies of the neural substrates of PPI of the acoustic startle reflex in rats and in humans with several neuropsychiatric disorders.
As discussed above, PPI is an operational measure of sensorimotor gating that is deficient in some neuropsychiatric disorders characterized clinically by deficient suppression or gating of intrusive sensory, motor or cognitive information. PPI is modulated by several neurotransmitters, with primary control exerted by D2 DAergic mechanisms, as well as glutamatergic, GABAergic, opiate and possibly cholinergic systems. The anatomical substrates that modulate PPI appear to include circuitry linking the hippocampus, nucleus accumbens, ventral pallidum and pedunculopontine nucleus; other brain regions that may modulate PPI include the dorsal striatum and thalamus. These pharmacological and anatomical substrates overlap significantly with substrates that are implicated in the pathophysiology of several psychiatric disorders of deficient sensory, motor or cognitive gating. The neural substrates of deficient sensorimotor gating have important pre-clinical and clinical implications that can be addressed experimentally in rats and humans.
